BGB-16673 showed high overall response rates in relapsed/refractory CLL/SLL, with a notable 94.4% response at the 200-mg dose level. Safety analysis revealed that 95.6% of patients experienced ...

Significant treatment options are changing the management of CLL, according to research presented at the ASH Annual Meeting 2025.

ORLANDO -- In a phase III trial with potential practice-changing implications, the non-covalent Bruton's tyrosine kinase (BTK ...

No difference in overall survival was observed between patients of different races who had chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and ...

Jaypirca showed higher overall response rates than Imbruvica in both treatment-naive and relapsed/refractory CLL/SLL populations. Progression-free survival trends favored Jaypirca, especially in ...

Zanubrutinib and venetoclax combination shows an 87% 36-month PFS rate in CLL/SLL patients, regardless of del (17p)/TP53 or IGHV status. The SEQUOIA trial demonstrates durable minimal residual disease ...

Zanubrutinib shows safety and efficacy in CLL/SLL patients, regardless of prior ibrutinib treatment, with lower treatment-limiting and cardiac adverse events compared to ibrutinib. The study included ...

Lilly’s Jaypirca scores big in first-line CLL/SLL, cutting progression risk by 80% and challenging rival BTK inhibitors.

Following the expanded approval, the accelerated approval for the later-line CLL/SLL was converted to a traditional approval.

Detailed price information for Ascentage Pharma Group Intl ADR (AAPG-Q) from The Globe and Mail including charting and trades.

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when ...

When Nathan was diagnosed with chronic lymphocytic leukemia (CLL) at just 45 years old, his world turned upside down overnight. As a military veteran and ER nurse, he was no stranger to facing ...